Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing novel, well tolerated, oral treatments of cancer, acute kidney injury and other serious illnesses.
Cantex is led by Stephen Marcus, M.D., Neil Flanzraich and Juan Rodriguez; seasoned drug developers and pharmaceutical executives with stellar track records of developing blockbuster products and extensive transactional experience.
Azeliragon is a safe, once-daily oral medication in Phase 2/3 development that targets glioblastoma, metastatic brain tumors, breast cancer, pancreatic cancer, and prevention of acute kidney injury in seriously ill patients.
September 2023 – Cantex Pharmaceuticals and Michigan Medicine announced the initiation of a randomized, double-blind, placebo-controlled, multicenter, Phase 3 pivotal clinical trial to evaluate the safety and efficacy of Cantex’s azeliragon in decreasing the incidence of acute kidney injury and other life-threatening complications in patients hospitalized for COVID-19.
September 2023 – Cantex Pharmaceuticals and Allegheny Health Network (AHN) announced the initiation of a Phase 1/2 study to assess the safety and efficacy of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer.
September 2023 – Cantex Pharmaceuticals and Lenox Hill Hospital’s Department of Neurological Surgery announced the initiation of a Phase 2 study to assess the safety and effectiveness of azeliragon in combination with radiation therapy as a treatment for newly diagnosed unmethylated glioblastoma.